CalciMedica, Inc. (CALC)Healthcare | Biotechnology | La Jolla, United States | NasdaqCM
0.82 USD
-0.11
(-12.065%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 0.80 -0.01 (-0.013%) ⇩ (July 13, 2026, 7:52 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 2:51 a.m. EDT
The investment case for CalciMedica has collapsed. The company is burning through cash with negative free cash flow and operating cash flow, while its balance sheet shows negative book value and negative equity. Fundamentally, the business is failing: it recently discontinued a Phase 2 trial for acute kidney injury, leaving its pipeline in jeopardy. The price action confirms this structural decline, dropping nearly 58% year-over-year and losing over 44% of its value across the last two years. While analysts offer a lofty $10.50 target, this ignores the reality of a biotech firm with no earnings, a shrinking market cap, and a discontinued key asset. The recent news of a director listing massive share holdings and the discontinuation of the KOURAGE trial signal insider distress and operational failure. With no dividend to cushion the blow and a trajectory of continuous devaluation, this is a clear avoid. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.204371 |
| AutoTheta | 0.262726 |
| AutoETS | 0.262936 |
| MSTL | 0.264664 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 25% |
| H-stat | 47.69 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.174 |
| Excess Kurtosis | -1.30 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 12,919,630 |
| Forward P/E | -0.50 |
| Beta | 1.11 |
| Website | https://calcimedica.com |
As of July 11, 2026, 2:51 a.m. EDT: Speculators are positioning for a sharp decline, evidenced by significant put volume at strikes far out-of-the-money ($4.00) relative to the current price, while call activity remains negligible. Implied volatility is elevated on the downside, suggesting fear of further deterioration rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.5991379 |
| Address1 | 505 Coast Boulevard South |
| Address2 | Suite 307 |
| All Time High | 8.59 |
| All Time Low | 0.461 |
| Ask | 0.955 |
| Ask Size | 1 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 891,200 |
| Average Daily Volume3 Month | 1,277,498 |
| Average Volume | 1,277,498 |
| Average Volume10Days | 891,200 |
| Beta | 1.106 |
| Bid | 0.8878 |
| Bid Size | 1 |
| Board Risk | 8 |
| Book Value | -0.07 |
| City | La Jolla |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.8178 |
| Current Ratio | 1.61 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 0.9247 |
| Day Low | 0.802 |
| Display Name | CalciMedica |
| Earnings Timestamp End | 1,755,288,000 |
| Earnings Timestamp Start | 1,754,942,400 |
| Ebitda | -22,197,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.516 |
| Enterprise Value | 11,455,630 |
| Eps Forward | -1.63 |
| Eps Trailing Twelve Months | -1.31 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.7809 |
| Fifty Day Average Change | 0.036899984 |
| Fifty Day Average Change Percent | 0.04725315 |
| Fifty Two Week Change Percent | -59.91379 |
| Fifty Two Week High | 7.2 |
| Fifty Two Week High Change | -6.3822 |
| Fifty Two Week High Change Percent | -0.8864167 |
| Fifty Two Week Low | 0.461 |
| Fifty Two Week Low Change | 0.3568 |
| Fifty Two Week Low Change Percent | 0.7739696 |
| Fifty Two Week Range | 0.461 - 7.2 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,686,749,400,000 |
| Float Shares | 3,100,680 |
| Forward Eps | -1.63 |
| Forward P E | -0.5017178 |
| Free Cashflow | -13,481,625 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 16 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.2745 |
| Held Percent Institutions | 0.3549 |
| Implied Shares Outstanding | 15,798,031 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-06-14 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California. |
| Long Name | CalciMedica, Inc. |
| Market | us_market |
| Market Cap | 12,919,630 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_34235142 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -19,544,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 14,733,243 |
| Number Of Analyst Opinions | 2 |
| Open | 0.91 |
| Operating Cashflow | -21,156,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 858 952 5500 |
| Post Market Change | -0.013399959 |
| Post Market Change Percent | -1.6385374 |
| Post Market Price | 0.8044 |
| Post Market Time | 1,783,986,755 |
| Previous Close | 0.93 |
| Price Hint | 4 |
| Price To Book | -11.682857 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.537 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.66667 |
| Region | US |
| Regular Market Change | -0.1122 |
| Regular Market Change Percent | -12.0645 |
| Regular Market Day High | 0.9247 |
| Regular Market Day Low | 0.802 |
| Regular Market Day Range | 0.802 - 0.9247 |
| Regular Market Open | 0.91 |
| Regular Market Previous Close | 0.93 |
| Regular Market Price | 0.8178 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 557,287 |
| Return On Assets | -0.81851995 |
| Return On Equity | -3.99509 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 15,798,031 |
| Shares Percent Shares Out | 0.1046 |
| Shares Short | 1,651,945 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 144,356 |
| Short Name | CalciMedica, Inc. |
| Short Percent Of Float | 0.3391 |
| Short Ratio | 0.49 |
| Source Interval | 15 |
| State | CA |
| Symbol | CALC |
| Target High Price | 15.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 10.5 |
| Target Median Price | 10.5 |
| Total Cash | 8,164,000 |
| Total Cash Per Share | 0.517 |
| Total Debt | 6,700,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.31 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.21329 |
| Two Hundred Day Average Change | -1.3954899 |
| Two Hundred Day Average Change Percent | -0.6305048 |
| Type Disp | Equity |
| Volume | 557,287 |
| Website | https://calcimedica.com |
| Zip | 92,037 |